Teladoc Health (NYSE:TDOC) Price Target Raised to $6.50

by · The Cerbat Gem

Teladoc Health (NYSE:TDOC – Free Report) had its price objective hoisted by Stifel Nicolaus from $5.50 to $6.50 in a research note released on Thursday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the health services provider’s stock.

A number of other brokerages have also weighed in on TDOC. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday, August 19th. Bank of America upped their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Canaccord Genuity Group dropped their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Citigroup cut their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus target price of $7.77.

Read Our Latest Stock Report on TDOC

Teladoc Health Price Performance

NYSE:TDOC opened at $8.52 on Thursday. The business has a 50 day simple moving average of $6.23 and a 200-day simple moving average of $6.47. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -9.91 and a beta of 2.14. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.89.

Teladoc Health (NYSE:TDOC – Get Free Report) last released its earnings results on Wednesday, October 28th. The health services provider reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The firm had revenue of $605.10 million for the quarter, compared to analysts’ expectations of $588.14 million. Teladoc Health had a negative return on equity of 11.52% and a negative net margin of 6.27%. The company’s quarterly revenue was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.28) earnings per share. As a group, analysts expect that Teladoc Health will post -0.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Teladoc Health news, CEO Charles III sold 17,805 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the sale, the chief executive officer directly owned 465,535 shares in the company, valued at $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is currently owned by company insiders.

Institutional Trading of Teladoc Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Teladoc Health in the 3rd quarter worth $60,000. Vise Technologies Inc. increased its position in Teladoc Health by 26.5% during the 3rd quarter. Vise Technologies Inc. now owns 22,035 shares of the health services provider’s stock valued at $128,000 after buying an additional 4,614 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in Teladoc Health by 9.5% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 186,825 shares of the health services provider’s stock valued at $1,084,000 after buying an additional 16,200 shares in the last quarter. Partners Wealth Management LLC purchased a new stake in Teladoc Health in the third quarter valued at about $58,000. Finally, Oppenheimer & Co. Inc. raised its stake in Teladoc Health by 11.5% in the third quarter. Oppenheimer & Co. Inc. now owns 206,625 shares of the health services provider’s stock valued at $1,198,000 after buying an additional 21,334 shares during the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

  • Positive Sentiment: Q3 results beat expectations. Teladoc reported a loss of $0.15 per share versus the $0.23 consensus loss, while revenue of approximately $605 million exceeded estimates by about 3.3%. Adjusted EBITDA reached roughly $79 million, near the high end of guidance. Teladoc Q3 loss and revenue results
  • Positive Sentiment: Cash flow and loss quality improved. Investors responded favorably to stronger free cash flow and adjusted EBITDA, suggesting that Teladoc is making progress on cost control even as revenue declined about 3% year over year. Teladoc stock rebounds as cash flow improves
  • Positive Sentiment: BetterHelp’s insurance strategy is gaining traction. BetterHelp generated $32 million in insurance revenue during Q3, and management expects the insurance-related business to reach an annualized run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, potentially reducing financial obligations. Teladoc BetterHelp insurance and convertible notes plans
  • Positive Sentiment: Deutsche Bank raised its price target to $11 from $10 and maintained a Buy rating, reinforcing the bullish reaction to the earnings report. Deutsche Bank Teladoc price target update
  • Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average may amplify momentum, but these are trading signals rather than fundamental improvements.
  • Negative Sentiment: Forward guidance remains mixed. Full-year revenue guidance of $2.4 billion matched consensus, but the FY 2026 EPS range of negative $0.95 to negative $0.75 brackets consensus at negative $0.81. Q4 revenue guidance also has a midpoint below analyst expectations, while the EPS range is wider and includes results below consensus.
  • Negative Sentiment: Stifel raised its price target to $6.50 but retained a Hold rating, and Needham reaffirmed Hold. These targets remain well below recent trading levels, highlighting valuation and execution concerns. Stifel Teladoc rating

About Teladoc Health

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.

Further Reading